Shen Y, et al. - Researchers sought to determine how pretreatment platelet-to-lymphocyte ratio (PLR), and lymphocyte-to-monocyte ratio (LMR) influence survival of hepatocellular carcinoma (HCC) patients who are undergoing transcatheter arterial chemoembolization (TACE) and radiofrequency ablation (RFA). They retrospectively analyzed and assigned 204 cases with HCC which accepted RFA and TACE into 2 groups based on optimal cutoff values for LMR (low: ≤ 2.13 or high: > 2.13) and PLR (low: ≤ 95.65 or high: > 95.65). Patients with a lower PLR vs those with a higher PLR had a longer overall survival (OS) (median OS, 20 vs 13 months), and patients with a higher LMR vs those with a lower LMR had a longer OS (OS, 22 vs 10 months). Findings thereby support the value of PLR and LMR as novel noninvasive circulating markers that may assist in assessing the prognosis of patients.